RxDoctor Payments Data

Katie O'Halloran

Family · Mattoon, ILNPI 1104427293

Payments from drug & device makers

$3,056in general payments, 2019–2025

Across 118 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$747
  • Abbott$444
  • Abiomed$276
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$226
  • Merck$211
  • Boehringer Ingelheim$206
  • plus $945 from 16 others

What the payments were for

  • Food & beverage$3,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,056 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$61,307
Medicare patients
198
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$17,923
EntrestoSacubitril/Valsartan29$17,697
JardianceEmpagliflozin19$12,996
FarxigaDapagliflozin Propanediol19$7,246
Midodrine Hcl12$1,348
Esomeprazole Magnesium12$1,087
Furosemide198$814
Metoprolol Succinate56$770
Valsartan30$666
Torsemide47$650
Hydralazine Hcl36$639
Potassium Chloride41$472
Duloxetine Hcl12$469
Hydroxychloroquine Sulfate11$415
Carbamazepine ErCarbamazepine12$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$747$17,69729 claims
Boehringer IngelheimJardiance$206$12,99619 claims
AstraZenecaFarxiga$68$7,24619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Mattoon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →